TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03118414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Participants were trained by exercise program based on their initial muscle strength and balance condition.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Exercise
Description: Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
Study: NCT03872375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal-Replacement Therapy
Description: The meal replacement shake, consumed once per day on two consecutive days, will over a given week lead to negative energy balance and induce weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.
Study: NCT02723773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK1437173A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK1437173A
Description: Intramuscular injection
Study: NCT03665636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: This is an open-label study. The UX007 (triheptanoin) starting dose will be 0.25 - 0.5 g/kg and titrated to a maximum of 2.5g/kg depending the on the subject's tolerance. The dose may be reduced if not tolerated. The compound will be administered 3-4 times per day, either at the end of a meal or with a snack. It should be given at least 2 hours apart from any cornstarch dose to allow each to act independent of one another, and to prevent the risk of increased gastrointestinal side effects. The doses may be held during episodes of gastroenteritis or diarrhea.
Study: NCT00436150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy-based treatment
Description: Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend weekly 1-hour sessions for 5 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants assigned to receive standard care will focus more on the health issues associated with pregnancy and postpartum. Both groups will attend weekly 1-hour sessions for 5 weeks.
Study: NCT03095651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-5160 16 nmol/kg
Description: MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-5160 16 nmol/kg
Description: MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-5160 32 nmol/kg
Description: MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-5160 32 nmol/kg
Description: MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-5160 64 nmol/kg
Description: MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-5160 64 nmol/kg
Description: MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Glargine 0.4 U/kg
Description: Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to Glargine
Description: Placebo to glargine, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to Glargine
Description: Placebo to glargine, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to Glargine
Description: Placebo to glargine, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to Glargine
Description: Placebo to glargine, subcutaneous injection administered daily for 12 days
Study: NCT03046108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blind injection of Morton neuroma
Description: Introduction of a needle based in anatomical landmark

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blind injection of Mepivacaine
Description: blind injection of 1 cc of Mepivacaine Normon 2% ®
Study: NCT03095651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to Glargine
Description: Placebo to glargine, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to Glargine
Description: Placebo to glargine, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-5160
Description: Placebo to MK-5160, subcutaneous injection administered daily for 12 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-5160
Description: Placebo to MK-5160, subcutaneous injection administered daily for 12 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: 20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: 20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: 20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: 20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: 20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: 20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: 20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: 20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Glargine 0.6 U/kg
Description: Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
Study: NCT00141453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Tablets 10, 20, or 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Matching placebo tablets
Study: NCT00132743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Stent

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Therapy
Description: Supervised exercise therapy, three times per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Therapy
Description: Supervised exercise therapy, three times per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol, 100 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol, 100 mg twice a day
Study: NCT02921035

Intervention type: DRUG
Intervention: Rebif (Interferon beta-1a)
Description: Rebif will be administered at a dose of 44 mcg, sc, tiw.
Study: NCT05433246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage therapy group
Description: Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
Study: NCT01657864

Intervention type: DRUG
Intervention: Lamotrigine
Description: Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder

Intervention type: DRUG
Intervention: Lamotrigine
Description: Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
Study: NCT00783523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline or Placebo
Description: Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline or Placebo
Description: Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
Study: NCT03820596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects.
Study: NCT02847377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of [18F]-ODS2004436 radiotracer
Study: NCT00119847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy
Description: Guideline-directed drug therapies after MI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy
Description: Guideline-directed drug therapies after MI
Study: NCT03291067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 1mg
Description: MT-8554 1mg QD, oral, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 5mg
Description: MT-8554 5mg QD, oral, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 10mg
Description: MT-8554 10mg QD, oral, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD, oral, 12 weeks
Study: NCT04156061

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delivery of CT scan results
Description: Method of results delivery - verbal or visual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delivery of CT scan results
Description: Method of results delivery - verbal or visual.
Study: NCT03648905

Intervention type: DRUG
Intervention: 13N-Ammonia
Description: a perfusion imaging agent

Intervention type: DRUG
Intervention: 13N-Ammonia
Description: a perfusion imaging agent

Intervention type: DRUG
Intervention: 13N-Ammonia
Description: a perfusion imaging agent

Intervention type: DRUG
Intervention: 13N-Ammonia
Description: a perfusion imaging agent

Intervention type: DRUG
Intervention: 18F-DOPA
Description: is a positron-emitting analog of the catechol amino acid, levodopa

Intervention type: DRUG
Intervention: 18F-DOPA
Description: is a positron-emitting analog of the catechol amino acid, levodopa

Intervention type: DRUG
Intervention: 18F-DOPA
Description: is a positron-emitting analog of the catechol amino acid, levodopa

Intervention type: DRUG
Intervention: 18F-DOPA
Description: is a positron-emitting analog of the catechol amino acid, levodopa

Intervention type: DRUG
Intervention: 11C-Methylreboxetine (11C-MRB)
Description: 11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.

Intervention type: DRUG
Intervention: 11C-Methylreboxetine (11C-MRB)
Description: 11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.

Intervention type: DRUG
Intervention: 11C-Methylreboxetine (11C-MRB)
Description: 11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.

Intervention type: DRUG
Intervention: 11C-Methylreboxetine (11C-MRB)
Description: 11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.

Intervention type: DRUG
Intervention: 18F-Dopamine
Description: is a positron-emitting analog of the catecholamine, dopamine

Intervention type: DRUG
Intervention: 18F-Dopamine
Description: is a positron-emitting analog of the catecholamine, dopamine

Intervention type: DRUG
Intervention: 18F-Dopamine
Description: is a positron-emitting analog of the catecholamine, dopamine

Intervention type: DRUG
Intervention: 18F-Dopamine
Description: is a positron-emitting analog of the catecholamine, dopamine
Study: NCT03724942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
Study: NCT03046108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blind injection of Mepivacaine
Description: blind injection of 1 cc of Mepivacaine Normon 2% ®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blind injection of Mepivacaine
Description: blind injection of 1 cc of Mepivacaine Normon 2% ®
Study: NCT00467077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: ZD1839 will be administered at a dose of 250 mg orally once daily,
Study: NCT03165487

Intervention type: OTHER
Intervention: Breast tissue collection
Description: During Breast Conservation Surgery, one sample will be collected before and after IORT.

Intervention type: OTHER
Intervention: Breast tissue collection
Description: During Breast Conservation Surgery, one sample will be collected before and after IORT.

Intervention type: OTHER
Intervention: Blood sample collection
Description: Blood will be collected before and after IORT, and at the two week follow-up.

Intervention type: OTHER
Intervention: Blood sample collection
Description: Blood will be collected before and after IORT, and at the two week follow-up.
Study: NCT03531489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIR-AD
Description: Non-significant risk medical device as decided by institutional review board

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIR-AD
Description: Non-significant risk medical device as decided by institutional review board
Study: NCT01316523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
Study: NCT02313766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPV : positive pressure ventilation
Description: Inspiratory pressure support ventilation (12 cmH2O) without PEEP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP : PPV + PEEP
Description: Inspiratory pressure support ventilation (12 cmH2O) with PEEP (6 cmH2O)
Study: NCT04323696

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Staple line suturing reinforcement methods - Plication and Over-sewing
Description: Sleeve gastrectomy procedure will be performed laparoscopically. The greater curvature of the stomach will be mobilised, and stomach will be sleeved using 39F calibration tube as the stent using 5-6 60 mm-stapler reloads depending on the length and thickness of the stomach. The staple-line is then reinforced using 3/0 absorbable sutures continuously throughout the staple-line. The two staple-line suturing methods in this study include over-sewing (through and through) and plication (Lembert).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Staple line suturing reinforcement methods - Plication and Over-sewing
Description: Sleeve gastrectomy procedure will be performed laparoscopically. The greater curvature of the stomach will be mobilised, and stomach will be sleeved using 39F calibration tube as the stent using 5-6 60 mm-stapler reloads depending on the length and thickness of the stomach. The staple-line is then reinforced using 3/0 absorbable sutures continuously throughout the staple-line. The two staple-line suturing methods in this study include over-sewing (through and through) and plication (Lembert).
Study: NCT03046108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blind injection of Triamcinolone
Description: blind injection of 40 mg of triamcinolone (trigon depot ®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blind injection of Triamcinolone
Description: blind injection of 40 mg of triamcinolone (trigon depot ®)
Study: NCT00419393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra XR (Levetiracetam XR)
Description: 500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
Study: NCT02767817

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stereotactic Hematoma Evacuation
Description: Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and then the drainage tube was pulled out.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs Transplantation
Description: Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas,and 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable Collagen Scaffold with MSCs Transplantation
Description: Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and injectable collagen scaffold combined with 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
Study: NCT02126722

Intervention type: PROCEDURE
Intervention: Gastroscopy
Description: Gastroscopy with multiple biopsies will be performed in all patients enrolled

Intervention type: PROCEDURE
Intervention: Gastroscopy
Description: Gastroscopy with multiple biopsies will be performed in all patients enrolled

Intervention type: DEVICE
Intervention: EndoFaster test
Description: During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.

Intervention type: DEVICE
Intervention: EndoFaster test
Description: During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.

Intervention type: OTHER
Intervention: Clo test
Description: During the gastroscopy the Clo test will be carried out in all patients enrolled.

Intervention type: OTHER
Intervention: Clo test
Description: During the gastroscopy the Clo test will be carried out in all patients enrolled.

Intervention type: OTHER
Intervention: Faecal Helicobacter pylori antigen
Description: On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.

Intervention type: OTHER
Intervention: Faecal Helicobacter pylori antigen
Description: On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.
Study: NCT02700308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Description: Placement and inflation of balloon prior to cement injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vertebroplasty
Description: Conventional vertebroplasty
Study: NCT03489863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Maintenance dose will be maintained for 10±3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Maintenance dose will be maintained for 10±3 days.